*Corresponding Author: N. Ramya Krishna, Email: ramyaphaniv@gmail.com ISSN 0976 – 3333 ORIGINAL RESEARCH ARTICLE Available Online at www.ijpba.info International Journal of Pharmaceutical & Biological Archives 2012; 3(4):1012-1016 Method Development and Validation of Lornoxicam in Pharmaceutical Dosage Form by Using UV-Visible Spectrophotometry N. Ramya Krishna *1 , K.V.Ramanjaneyulu 1 , M.Deepti Kiranmayi 1 , Dr. A.M.S. Sudhakar Babu 2 P. Venkateswara Rao , 3 , N. Pramod 3 1 Department of Pharmaceutical Analysis, 2 Department of Pharmaceutics, 3 Department of Pharma Chemistry, A.M.Reddy Memorial College of Pharmacy, Narasarao Pet, Guntur, AP, India Received 28 May 2012; Revised 12 Aug 2012; Accepted 19 Aug 2012 ABSTRACT Lornoxicam is a Non steroidal anti inflammatory drug (NSAID) of the oxicam class with analgesic, anti– inflammatory and antipyretic properties. Three simple UV-Visible spectrophotometric methods were developed for the determination of lornoxicam in pharmaceutical dosage form. Method A was UV method, Lornoxicam exhibiting λ max at 377nm in 0.02 N NaOH and obeyed linearity in the concentration range of 5-30μg. The proposed method was statistically validated. The method (B) is based on the formation of chloroform extractable ion-association complexes of lornoxicam with Alizarin red S (Method B) exhibiting absorption maximum at 440nm. Method C is diazotization of Para nitro Aniline (PNA) with sodium nitrate followed by coupling with drug in alkaline medium (PNA Method) exhibiting absorption maximum at 420nm. Linearity ranges and RSD will be 5-30ppm and 0.2106 for Method A and 50-250ppm and 0.495 for Method B and 5-30ppm and 1.023 for method C. All these methods are Accurate, precise and very effective even at low concentrations and used for the quantitative estimation of Lornoxicam in commercial formulations. Key words: Lornoxicam, uv-visible spectrophotometry methods, 0.02N NaOH, ARS, PNA. INTRODUCTION Lornoxicam is a non steroidal anti inflammatory drug (NSAID) .It belongs to oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties. It works by blocking the action of Cyclooxygenase, an enzyme involved in the production of chemicals, including some prostaglandins in the body [1] . It is available in oral and parentral formulations. It is distinguished from established oxicams by a relatively short elimination half-life (3 to 5 hours), which may be advantageous from a tolerability standpoint Figure 1: Structure of Lornoxicam [2]. Data from preliminary clinical trials suggest that lornoxicam is as effective as the opioid analgesics morphine, pethidine (meperidine) and tramadol in relieving postoperative pain following gynaecological or orthopaedic surgery, and as effective as other NSAIDs after oral surgery. Lornoxicam was also as effective as other NSAIDs in relieving symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain [3] The severe or irreversible adverse effects of Lornoxicam, which give rise to further complications include Anemia, Thrombocytopenia, Leucopenia, Hypertension, Hypersensitivity ,Skin reactions, Palpitation . Lornoxicam has a tolerability profile characteristic of an NSAID, with gastrointestinal disturbances being the most common adverse events. [4] . Lornoxicam produces potentially life-threatening effects which include discontinuation of Lornoxicam therapy. The signs and symptoms that are produced after the acute overdosage of Lornoxicam include Nausea, Vomiting, Coma, Ataxia, Dizziness, Coagulopathy, Renal damage.